Stephen Industries

StemSight is a Finnish biotechnology company developing innovative cell therapies for treating blindness. Its proprietary platform uses induced pluripotent stem cells (iPSCs) and biomaterials, initially targeting rare diseases like limbal stem cell deficiency, with plans to expand to major corneal blindness conditions.

Gesynta Pharma AB is a clinical-stage pharmaceutical company based in Stockholm, Sweden, founded in 2017. The company focuses on developing compounds that inhibit the pro-inflammatory enzyme microsomal prostaglandin E synthase-1 (mPGES-1) to address chronic inflammatory conditions, particularly in cardiovascular diseases and cancer. Its most advanced drug candidate, vipoglanstat (GS-248), is being developed as a non-hormonal treatment for endometriosis, a painful condition affecting around 10 percent of women of reproductive age. Clinical studies have indicated that vipoglanstat significantly reduces endometriotic lesions and provides pain relief, with preparations underway for a phase II clinical trial. Additionally, Gesynta Pharma is advancing another candidate, GS-073, which is set to enter phase I clinical trials for a different inflammatory condition. The company's research is rooted in work from the Karolinska Institutet, and it aims to deliver safe and effective treatments for serious diseases.

Hycamite TCD Technologies is a private company that specializes in commercializing innovative environmental technologies. It focuses on developing clean hydrogen production methods, notably through processing methane without generating carbon dioxide emissions.

Fiberwood manufactures eco-friendly wood fiber insulation boards using foam-forming technology. Their products are entirely bio-based, containing no plastic or fossil materials, and aim to promote sustainable construction and packaging.

NPHarvest specializes in transforming organic waste and wastewater into valuable fertilizer, thereby reducing environmental impact. The company employs energy-efficient membrane stripping and lime-based phosphorus recovery techniques to recycle nitrogen and phosphorus, creating a cost-effective and sustainable nutrient source for agriculture.

Ninyes operates a Resale-as-a-Service platform that enables fashion brands to profit from the growing secondhand market. Its proprietary technology, Ninyes ResaleCore, integrates software, garment intake, logistics, and branded fulfillment, allowing brands of all sizes to capture value from resale.

Hycamite TCD Technologies is a private company that specializes in commercializing innovative environmental technologies. It focuses on developing clean hydrogen production methods, notably through processing methane without generating carbon dioxide emissions.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Fiberwood manufactures eco-friendly wood fiber insulation boards using foam-forming technology. Their products are entirely bio-based, containing no plastic or fossil materials, and aim to promote sustainable construction and packaging.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.